Treatment of influenza A (H1N1) virus infection with ribavirin aerosol.
In a randomized, controlled study of ribavirin aerosol treatment of influenza A(H1N1) virus infection among college students, treated patients had a significantly shorter duration of fever than control patients. There was a trend of more rapid recovery in treated patients. Virus shedding was similar in treated and control patients, declining gradually from a 50% tissue culture infective dose of 3.5 log10 per ml at admission to 1.8 log10 per ml at 53 h after admission. There was no local or systemic intolerance and no hematological or biochemical abnormalities associated with ribavirin treatment.
D000336:Aerosols; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D009980:Influenza A virus / Q000187:drug effects; D007251:Influenza, Human / Q000188:drug therapy* / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D012263:Ribonucleosides / Q000627:therapeutic use*
D000336:Aerosols; D012263:Ribonucleosides; D012254:Ribavirin